The global HPV therapeutic vaccines market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are fuelling the growth of the market include a growing number of cervical cancer patients globally, due to HPV infection, along with growing awareness about health among the people. Moreover, the increasing incidence of HPV is a major driving factor for the market. However, low adoption rates and stringent regulatory policies requiring long-term studies of vaccines and their efficacies are the hindrance factors for the market growth.

Human papillomavirus (HPV) therapeutic vaccines are used to protect against HPV infections. They are sexually transmitted through the skin and mucous of the infected person. Sexually transmitted HPV infection can be categorized as low-risk HPVs and high-risk HPVs. Low-risk HPV causes skin warts around genitals, anus, mouth, or throat, and could lead to respiratory papillomatosis; whereas, high-risk HPV causes cancer such as cervical, anal, oropharyngeal cancers, and other rare cancers. The incidence of genital HPV infections in the US is approximately 14 million per year. Currently, there are three FDA-approved HPV therapeutic vaccines available in the market, namely, Gardasil, Gardasil 9, and Cervarix. These vaccines are effective in preventing infections caused by two high-risk HPVs (HPV types 16 and 18), which are responsible for causing about 70% of cervical cancers. Thus, the rise in the cases of HPV is driving the growth of the market. The key players in the market are adopting several strategies such as product launches, and mergers and acquisitions, among others to remain competitive in the market. For instance, In September 2019, GlaxoSmithKline teamed up with China-based company Xiamen Innovax Biotech for the development and commercialization of HPV vaccines.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Pfizer Inc., GlaxoSmithKline plc, and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global HPV Therapeutic Vaccines Market Report by Segment

By Adjuvants 

• Bivalent HPV Vaccine 

• Quadrivalent HPV Vaccine

Global HPV Therapeutic Vaccines Market by Region